| Name | Title | Contact Details |
|---|
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.
Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.
Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.
Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.
Explora BioLabs is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.